Verastem (VSTM) Research & Development (2011 - 2026)
Verastem (VSTM) posted quarterly Research & Development of $38.2 million for Q1 2026, up 31.1% year-over-year from $29.2 million in Q1 2025, and up 20.66% quarter-over-quarter from $31.7 million in Q4 2025.
Analysis
Verastem (VSTM) Research & Development (2011 - 2026) Analysis & Trends
Verastem's Research & Development history runs 16 years deep, the most recent figure standing at $38.2 million for Q1 2026.
- In Q1 2026, Research & Development rose 31.1% year-over-year to $38.2 million; the TTM figure through Mar 2026 stood at $123.7 million (up 33.29% YoY), while the FY2025 annual figure was $114.6 million, up 40.9% from the prior year.
- Research & Development for Q1 2026 stood at $38.2 million, up from $31.7 million in the prior quarter.
- The five-year high for Research & Development was $38.2 million in Q1 2026, with the low at $10.7 million in Q4 2022.
- The 5-year median for Research & Development is $18.1 million (2024), against an average of $20.4 million.
- Peak annual rise in Research & Development reached 109.52% in 2023, while the deepest fall reached 13.4% in 2023.
- Verastem's Research & Development stood at $10.7 million in 2022, then surged by 109.52% to $22.5 million in 2023, then fell by 7.51% to $20.8 million in 2024, then jumped by 52.2% to $31.7 million in 2025, then rose by 20.66% to $38.2 million in 2026.
- Business Quant data shows VSTM's Research & Development at $38.2 million in Q1 2026, $31.7 million in Q4 2025, and $29.0 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | -486.00 Mn |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | 651.00 Mn |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | 394.92 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 612.28 Mn |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 97.90 Mn |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Verastem | 815.95 Mn | 679.59 Mn | 36.32 Mn | 41.34 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 41.34 Mn |
| Mar 31, 2026 | 38.22 Mn |
| Dec 31, 2025 | 31.67 Mn |
| Sep 30, 2025 | 28.99 Mn |
| Jun 30, 2025 | 24.79 Mn |
| Mar 31, 2025 | 29.15 Mn |
| Dec 31, 2024 | 20.81 Mn |
| Sep 30, 2024 | 24.75 Mn |
| Jun 30, 2024 | 18.06 Mn |
| Mar 31, 2024 | 17.71 Mn |
| Dec 31, 2023 | 22.50 Mn |
| Sep 30, 2023 | 13.95 Mn |
| Jun 30, 2023 | 12.89 Mn |
| Mar 31, 2023 | 12.02 Mn |
| Dec 31, 2022 | 10.74 Mn |
| Sep 30, 2022 | 11.29 Mn |
| Jun 30, 2022 | 14.89 Mn |
| Mar 31, 2022 | 13.64 Mn |
| Dec 31, 2021 | 11.40 Mn |
| Sep 30, 2021 | 9.33 Mn |